105.18
전일 마감가:
$105.09
열려 있는:
$105.06
하루 거래량:
3.15M
Relative Volume:
0.93
시가총액:
$8.95B
수익:
-
순이익/손실:
$-153.72M
주가수익비율:
-52.59
EPS:
-2
순현금흐름:
$-103.81M
1주 성능:
-0.11%
1개월 성능:
+16.25%
6개월 성능:
+83.56%
1년 성능:
+365.19%
Verona Pharma Plc Adr Stock (VRNA) Company Profile
명칭
Verona Pharma Plc Adr
전화
011-44-0-2032834200
주소
3 MORE LONDON RIVERSIDE, LONDON
VRNA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VRNA
Verona Pharma Plc Adr
|
105.18 | 8.95B | 0 | -153.72M | -103.81M | -2.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2025-07-01 | 개시 | Wolfe Research | Outperform |
2025-04-28 | 개시 | TD Cowen | Buy |
2025-04-21 | 개시 | Cantor Fitzgerald | Overweight |
2025-01-10 | 개시 | ROTH MKM | Buy |
2024-10-03 | 개시 | Wells Fargo | Overweight |
2023-05-22 | 재개 | Jefferies | Buy |
2022-09-19 | 재개 | Wedbush | Outperform |
2022-08-26 | 개시 | Piper Sandler | Overweight |
2021-09-13 | 개시 | H.C. Wainwright | Buy |
2020-08-25 | 개시 | Jefferies | Buy |
2020-08-10 | 개시 | Canaccord Genuity | Buy |
2019-04-18 | 개시 | BTIG Research | Buy |
모두보기
Verona Pharma Plc Adr 주식(VRNA)의 최신 뉴스
Merck Q2: EPS Beats, but Sales Flat as Vaccine Demand Slips Globally - Investing.com
Verona Pharma stock hits all-time high at 105.31 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock hits all-time high at 105.31 USD - Investing.com
Verona Pharma Plc ADR’s Shares Reel: 69.24% Quarterly Revenue Decline Amid 8.93B Market Cap - investchronicle.com
Verona Pharma stock reaches all-time high at 105.0 USD By Investing.com - Investing.com India
Verona Pharma stock reaches all-time high at 105.0 USD - Investing.com Australia
Merck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug Portfolio - MSN
Pharmaceutical Stocks To Research – July 12th - Defense World
Top Medical Stocks To Follow Now – July 12th - Defense World
Wells Fargo Downgrades Verona Pharma plcDepositary Receipt () (VRNA) - MSN
Merck stock rises as UBS reiterates Buy rating after Verona Pharma acquisition By Investing.com - Investing.com South Africa
Merck to acquire Verona Pharma stock for $107 per ADS in $10 billion deal By Investing.com - Investing.com South Africa
Verona Pharma stock rating downgraded to Neutral by Roth/MKM after Merck offer - Investing.com South Africa
Merck to Acquire Verona Pharma for $10 Billion in Bid to Cushion "Patent Cliff" Impact - Mitrade
Verona Pharma stock hits all-time high at 104.83 USD By Investing.com - Investing.com South Africa
American pharmaceutical company Merck acquires British Verona Pharma for $10 billion - AKM.RU
Verona Pharma stock hits all-time high at 104.83 USD - Investing.com
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck - Nasdaq
Merck to acquire Verona Pharma for $10 billion By Investing.com - Investing.com Nigeria
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma - MarketWatch
Merck to acquire Verona Pharma for $10 billion - Investing.com Australia
Can Verona Pharma Plc ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Starbucks, Freeport-McMoran and Verona Pharma rise premarket; WPP, T-Mobile fall By Investing.com - Investing.com South Africa
Merck compra por 10.000 millones de dólares Verona Pharma - Yahoo Finanzas
Best Momentum Stock To Buy For July 7th - Barchart.com
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - Yahoo Finance
Up 515%, Watch This Biopharma Breakout - inkl
Verona Pharma: A Blockbuster Franchise In The Making - Seeking Alpha
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today - Barchart.com
Piper Sandler reiterates Verona Pharma stock rating and target By Investing.com - Investing.com UK
21 Best-Performing Small-Cap Stocks for June 2025 - NerdWallet
Verona Pharma (VRNA) Shares Soar 5.47% to Record High - AInvest
Verona Pharma ADR Surges, Matches Key 52-Week High: What’s Fueling the Rally? - Daily Chhattisgarh News
Verona Pharma stock soars to all-time high of $77.08 By Investing.com - Investing.com Nigeria
FDA Approves GSK's Nucala for Expanded Use in COPD - Zacks Investment Research
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Verona Pharma stock soars to all-time high of $74.36 By Investing.com - Investing.com UK
Market Update: Verona Pharma Plc ADR (VRNA) Sees Negative Movement, Closing at 69.14 - DWinneX
Verona Pharma Plc ADR (NASDAQ: VRNA): An Enticing Stock To Watch - Stocksregister
IBD Stock Of The Day Verona Pharma Tests Buy Point After Earnings Breakout - Investor's Business Daily
Verona Pharma’s general counsel sells shares worth $234,126 By Investing.com - Investing.com India
Verona Pharma director Vikas Sinha sells $178,416 in stock By Investing.com - Investing.com South Africa
Verona Pharma’s general counsel sells shares worth $234,126 - Investing.com
Verona Pharma Plc ADR (VRNA)’s Market Momentum: Closing Strong at 72.07, Down -1.56 - DWinneX
What is Verona Pharma Plc ADR (VRNA) Stock Return on Shareholders’ Capital? - Sete News
Verona Pharma Plc ADR [VRNA] Stock trading around $73.21 per share: What’s Next? - dbtnews.com
VRNA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Watch this stock’s price performance: Verona Pharma Plc ADR (NASDAQ:VRNA) - uspostnews.com
Verona Pharma ADR earnings beat by $0.05, revenue topped estimates - Investing.com UK
Verona Pharma Plc ADR (NASDAQ: VRNA) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
Verona Pharma Plc Adr (VRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):